Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Trial Profile

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Netarsudil (Primary) ; Timolol
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms Rocket 3
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2017 Status changed from active, no longer recruiting to completed, according to an Aerie Pharmaceuticals media release.
    • 24 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
    • 24 Aug 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top